The Stabilization Of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial: Primary Results
Dr Michelle O'Donoghue, Brigham and Women's Hospital (Boston, USA)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies
The differences of the effects on lipid-lowering actions and glucose metabolisms between rosuvastatin and atorvastatin in Japanese diabetic patients with hyperlipidemia (LISTEN trial)
Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients
Abstracts linked to ESC press conferences are not available until embargo lifts. The embargo lifts at the beginning of the press conference or the scientific session, whichever comes first. All other abstracts will be online on 22 August, 2014 in the Scientific Programme Planner except for Hot Lines, Clinical Trial Update and Registries Hot Lines abstracts.
Press releases are available on site in the press kit (USB key) that you will receive once you pick up your badge at the press registration desk at ESC Congress 2014 - except for press releases on Clinical Trial Updates and Hot Line sessions which are only available when the embargo lifts.
Press slides will be available at the beginning of the press conference.
All ESC Press conferences will be broadcasted live. Unfortunately, no webcast will be available. Access to the session will be restricted to registered press only.
During the ESC Congress 2014, all scientific resources are available on ESC Congress 365.